Geode Capital Management LLC Has $734,000 Position in Metagenomi, Inc. (NASDAQ:MGX)

Geode Capital Management LLC increased its holdings in shares of Metagenomi, Inc. (NASDAQ:MGX) by 105.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 338,031 shares of the company’s stock after acquiring an additional 173,796 shares during the quarter. Geode Capital Management LLC owned about 0.90% of Metagenomi worth $734,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Jacobs Levy Equity Management Inc. increased its holdings in shares of Metagenomi by 209.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company’s stock worth $296,000 after acquiring an additional 92,468 shares during the last quarter. Verition Fund Management LLC acquired a new position in shares of Metagenomi during the 3rd quarter worth approximately $82,000. BNP Paribas Financial Markets grew its holdings in Metagenomi by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock valued at $28,000 after buying an additional 7,256 shares in the last quarter. Green Alpha Advisors LLC acquired a new position in Metagenomi in the 3rd quarter valued at $69,000. Finally, Novo Holdings A S grew its holdings in Metagenomi by 3.5% in the 2nd quarter. Novo Holdings A S now owns 1,800,000 shares of the company’s stock valued at $7,344,000 after buying an additional 60,825 shares in the last quarter.

Metagenomi Stock Performance

Shares of NASDAQ MGX opened at $3.13 on Friday. Metagenomi, Inc. has a 52 week low of $1.61 and a 52 week high of $12.74. The stock’s fifty day moving average is $2.79 and its 200 day moving average is $2.99.

Analysts Set New Price Targets

MGX has been the topic of a number of research reports. Chardan Capital reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Metagenomi in a report on Wednesday, November 20th. HC Wainwright upped their price objective on Metagenomi from $7.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, December 10th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Metagenomi presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.67.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.